1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Investor Presentation
Financial Results, Press Release
Appoints Charles Newton to its Board of Directors
Announces Participation at Upcoming Healthcare Conferences
Reports Third Quarter 2025 Financial Results
Announces Plan for Return of $375 Million in Excess Capital
FY 2025
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Tender Offer Statement by Issuer